Nascent Biotech Inc.
NBIODelisted- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001622057
Nascent Biotech Inc. was delisted in 2024; its insiders filed their last Form 4 on Jul 2, 2024; no institution reported holding it in 13F filings for Q3 2024; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 0
- Q3 2024
- 13F value
- $0
- Reported value at the end of Q3 2024
- Superinvestors holding
- 0
- At the end of Q3 2024
Superinvestors holding NBIO, Q3 2024
No superinvestor reported holding NBIO at the end of Q3 2024.
Latest insider trades
Open-market purchases and sales by Nascent Biotech Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 9, 2023 (view filing)3:28 PM ET | Jun 7 | 2 days | Holden Lowell ThomasCFO | PPurchase | +130.0K | $0.04 | +$5.20K | +1.6%8.41M after | |
| Feb 2, 2023 (view filing)3:04 PM ET | Jan 27 | 6 daysLate | Holden Lowell ThomasCFO | PPurchase | +20.0K | $0.14 | +$2.80K | +0.2%8.42M after | Duplicate filing |
| Feb 2, 2023 (view filing)12:47 PM ET | Jan 27 | 6 daysLate | Holden Lowell ThomasCFO | PPurchase | +20.0K | $0.14 | +$2.80K | +0.2%8.42M after | |
| Jul 25, 2022 (view filing)11:24 AM ET | Jul 21 | 4 days | Holden Lowell ThomasCFO | SSale | −5.00K | $0.26 | −$1.30K | −0.1%8.11M after |
Top 10 13F holders, Q3 2024
The largest institutional positions in Nascent Biotech Inc. at the end of Q3 2024; share changes are against Q2 2024.
No institution reported holding NBIO in 13F filings for Q3 2024.